Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply
ContributorsGabay, Cem; Kavanaugh, Arthur
Published inLancet, vol. 382, no. 9890, 395
Publication date2013
Keywords
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antirheumatic Agents/therapeutic use
- Arthritis, Rheumatoid/therapy
- Female
- Humans
- Male
Affiliation entities
Research groups
Citation (ISO format)
GABAY, Cem, KAVANAUGH, Arthur. Tocilizumab versus adalimumab for rheumatoid arthritis - Authors” reply. In: Lancet, 2013, vol. 382, n° 9890, p. 395. doi: 10.1016/S0140-6736(13)61670-0
Main files (1)
Article (Published version)
Identifiers
- PID : unige:73679
- DOI : 10.1016/S0140-6736(13)61670-0
- PMID : 23911377
Journal ISSN0140-6736
